US20220362248A1 - Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer - Google Patents
Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer Download PDFInfo
- Publication number
- US20220362248A1 US20220362248A1 US17/579,187 US202217579187A US2022362248A1 US 20220362248 A1 US20220362248 A1 US 20220362248A1 US 202217579187 A US202217579187 A US 202217579187A US 2022362248 A1 US2022362248 A1 US 2022362248A1
- Authority
- US
- United States
- Prior art keywords
- palbociclib
- benzo
- day
- dihydro
- fluoropropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960004390 palbociclib Drugs 0.000 title claims abstract description 66
- 201000011510 cancer Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- KISZAGQTIXIVAR-VWLOTQADSA-N 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(CCC1)C=C(C=C2)C(=O)O)C1=CC=C(C=C1)O[C@@H]1CN(CC1)CCCF KISZAGQTIXIVAR-VWLOTQADSA-N 0.000 title claims abstract description 15
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 25
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 102100038595 Estrogen receptor Human genes 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 108010038795 estrogen receptors Proteins 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- ZLXABOVOCSRKAL-KRWDZBQOSA-N FCCCN1C[C@H](CC1)OC1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C Chemical compound FCCCN1C[C@H](CC1)OC1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C ZLXABOVOCSRKAL-KRWDZBQOSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- VDDLELYAGVIJDH-QHCPKHFHSA-N methyl 5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate Chemical compound FCCCN1C[C@H](CC1)OC1=CC=C(C=C1)C1=CCCCC2=C1C=CC(=C2)C(=O)OC VDDLELYAGVIJDH-QHCPKHFHSA-N 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UFYWXGZURXVCOB-UHFFFAOYSA-N methyl 5-(trifluoromethylsulfonyloxy)-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate Chemical compound FC(S(=O)(=O)OC1=CCCCC2=C1C=CC(=C2)C(=O)OC)(F)F UFYWXGZURXVCOB-UHFFFAOYSA-N 0.000 description 6
- AXDYGPIMKPWMQH-UHFFFAOYSA-N methyl 5-oxo-6,7,8,9-tetrahydrobenzo[7]annulene-2-carboxylate Chemical compound C1CCCC(=O)C=2C1=CC(C(=O)OC)=CC=2 AXDYGPIMKPWMQH-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- BTNQNKNJHAKTED-UHFFFAOYSA-N (5-oxo-6,7,8,9-tetrahydrobenzo[7]annulen-2-yl) trifluoromethanesulfonate Chemical compound C1CCCC(=O)C=2C1=CC(OS(=O)(=O)C(F)(F)F)=CC=2 BTNQNKNJHAKTED-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- DKLNTYKCFSFDCG-UHFFFAOYSA-N (5-oxo-6,7,8,9-tetrahydrobenzo[7]annulen-2-yl) 2,2-dimethylpropanoate Chemical compound CC(C(=O)OC=1C=CC2=C(CCCCC2=O)C=1)(C)C DKLNTYKCFSFDCG-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- BSTFWDMCHMXBIU-QFIPXVFZSA-N 5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol Chemical compound FCCCN1C[C@H](CC1)OC1=CC=C(C=C1)C1=CCCCC2=C1C=CC(=C2)O BSTFWDMCHMXBIU-QFIPXVFZSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- IGBNIJNNNITECR-QFIPXVFZSA-N [5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-yl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC1=CC2=C(C(=CCCC2)C2=CC=C(C=C2)O[C@@H]2CN(CC2)CCCF)C=C1)(F)F IGBNIJNNNITECR-QFIPXVFZSA-N 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- BJVTYIQRIDCBLG-VWLOTQADSA-N 3-[5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-yl]-2,2-dimethylpropanoic acid Chemical compound CC(C)(Cc1ccc2c(CCCC=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1)C(O)=O BJVTYIQRIDCBLG-VWLOTQADSA-N 0.000 description 3
- MKUJUQWPQBXXEM-AWEZNQCLSA-N CC1(OB(OC1(C)C)C1=CC=C(O[C@@H]2CNCC2)C=C1)C Chemical compound CC1(OB(OC1(C)C)C1=CC=C(O[C@@H]2CNCC2)C=C1)C MKUJUQWPQBXXEM-AWEZNQCLSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 3
- OBHBEVRNXKFPKO-UHFFFAOYSA-N [5-(trifluoromethylsulfonyloxy)-8,9-dihydro-7H-benzo[7]annulen-2-yl] 2,2-dimethylpropanoate Chemical compound CC(C(=O)OC1=CC2=C(C(=CCCC2)OS(=O)(=O)C(F)(F)F)C=C1)(C)C OBHBEVRNXKFPKO-UHFFFAOYSA-N 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- PAFURZJCCMSKNY-UHFFFAOYSA-N methyl 6-(2,4-dichlorophenyl)-5-[4-[1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate Chemical compound COC(=O)C=1C=CC2=C(CCCC(=C2C2=CC=C(C=C2)OC2CN(CC2)CCCF)C2=C(C=C(C=C2)Cl)Cl)C=1 PAFURZJCCMSKNY-UHFFFAOYSA-N 0.000 description 3
- DXHNVMQDQUEYKK-FTBISJDPSA-N methyl 6-bromo-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate hydrobromide Chemical compound Br.COC(=O)c1ccc2c(CCCC(Br)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1 DXHNVMQDQUEYKK-FTBISJDPSA-N 0.000 description 3
- 229940061338 palbociclib 100 mg Drugs 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SGHPXNIINLLSMV-KRWDZBQOSA-N tert-butyl (3s)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OC1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 SGHPXNIINLLSMV-KRWDZBQOSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- LCEJOJCDTXCOCR-UHFFFAOYSA-N 2-hydroxy-6,7,8,9-tetrahydrobenzo[7]annulen-5-one Chemical compound C1CCCC(=O)C=2C1=CC(O)=CC=2 LCEJOJCDTXCOCR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- YDCDQLPZRXYIRX-UQKRIMTDSA-N Cl.CC1(OB(OC1(C)C)C1=CC=C(O[C@@H]2CNCC2)C=C1)C Chemical compound Cl.CC1(OB(OC1(C)C)C1=CC=C(O[C@@H]2CNCC2)C=C1)C YDCDQLPZRXYIRX-UQKRIMTDSA-N 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 229940061301 ibrance Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1Cl QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- URBUZQPPQLQHBZ-UHFFFAOYSA-N 1-fluoro-3-iodopropane Chemical compound FCCCI URBUZQPPQLQHBZ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- BICZJRAGTCRORZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1 BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 1
- -1 9-(trifluoromethanesulfonyloxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl-2,2-dimethylpropanoate Chemical compound 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- HEZXIYUDMUQDHU-QFIPXVFZSA-N Br.COC(=O)c1ccc2c(c1)CCCC(Br)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 Chemical compound Br.COC(=O)c1ccc2c(c1)CCCC(Br)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 HEZXIYUDMUQDHU-QFIPXVFZSA-N 0.000 description 1
- VPRIYNALCNNRQK-UHFFFAOYSA-N Br[BrH]Br.C1=CC=NC=C1.[Ar] Chemical compound Br[BrH]Br.C1=CC=NC=C1.[Ar] VPRIYNALCNNRQK-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- JHPSANRMHGRDLI-OGFXRTJISA-N C(=O)(OC(C)(C)C)N1C[C@@H](CC1)O.[Ar] Chemical compound C(=O)(OC(C)(C)C)N1C[C@@H](CC1)O.[Ar] JHPSANRMHGRDLI-OGFXRTJISA-N 0.000 description 1
- OVEJEBOIPFOAGD-HNNXBMFYSA-N CB(O)N1CC[C@H](Oc2ccc(B3OC(C)(C)C(C)(C)O3)cc2)C1 Chemical compound CB(O)N1CC[C@H](Oc2ccc(B3OC(C)(C)C(C)(C)O3)cc2)C1 OVEJEBOIPFOAGD-HNNXBMFYSA-N 0.000 description 1
- UTMYPTVTWJVTOM-VWLOTQADSA-N CC(C)(C)C(=O)Oc1ccc2c(c1)CCCC=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 Chemical compound CC(C)(C)C(=O)Oc1ccc2c(c1)CCCC=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 UTMYPTVTWJVTOM-VWLOTQADSA-N 0.000 description 1
- PAFURZJCCMSKNY-SANMLTNESA-N COC(=O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 Chemical compound COC(=O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1 PAFURZJCCMSKNY-SANMLTNESA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 229940082819 Luteinizing hormone releasing hormone (LHRH) agonist Drugs 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010050283 Tumour ulceration Diseases 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- UBOIOTWHERUBJL-UHFFFAOYSA-N argon;pyridine Chemical compound [Ar].C1=CC=NC=C1 UBOIOTWHERUBJL-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102220197818 rs1057519717 Human genes 0.000 description 1
- 102220080548 rs141368794 Human genes 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the estrogen receptor a (ESR1) is expressed in the majority of breast tumors, enabling them to respond to the mitogenic actions of estrogens.
- compound (1) 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, hereafter designated as “compound (1)”, is a selective estrogen receptor degrader (SERD) which has complete estrogen receptor antagonist properties and accelerates the proteasomal degradation of the estrogen receptor.
- SESD selective estrogen receptor degrader
- Palbociclib also known as 6-acetyl-8-cyclopentyl-5-methyl-2-[5-(1-piperazinyl)pyridine-2-ylamino]pyrido[2,3-d]pyrimidin-7(8H)-one, is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
- Palbociclib is marketed under the tradename Ibrance® and is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor, or in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
- LHRH luteinizing hormone-releasing hormone
- FIG. 1 Synthetic scheme for the synthesis of compound (1).
- FIG. 2 Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice, showing tumor volume evolution (tumor volume in mm 3 versus days of treatment).
- FIG. 3 Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice, showing tumor volume changes from baseline on day 51 of treatment.
- compound (1) may exist not only in the form of a zwitterion (i.e. a globally neutral molecule having an acid group and a basic group), but also in the form of addition salts with acids or bases. Such addition salts may be used in the above combination.
- a combination comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib.
- the combination of compound (1), or a pharmaceutically acceptable salt thereof, with palbociclib shows therapeutic synergy.
- a combination demonstrates therapeutic synergy if its therapeutic effect is superior compared to the cumulative effect of either active agent of the combination alone.
- compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib are administered by the oral route.
- composition comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib, as well as at least one pharmaceutically acceptable excipient.
- excipients are selected from the customary excipients which are known to a person skilled in the art. More particularly, the excipients are selected from those useful for oral administration in whatever form (liquid solution, dispersion or suspension, tablets, capsules or the like).
- compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib may be administered simultaneously, separately, or spaced out over a period of time (sequential administration). Therefore, the combination provided herein is not exclusively limited to the one which is obtained by physical association of the constituents in a single pharmaceutical composition, but also to those which allow a separate administration, which can be simultaneous or spaced out (or “spread out”) over time.
- a pharmaceutical kit which comprises:
- compositions (i) and (ii) being in separate compartments and being intended to be independently administered, each administration with regards to the other one being simultaneous, separated or spread out (sequential) overtime.
- the compound (1) or pharmaceutically acceptable salt thereof and palbociclib are advantageously present at effective doses, adapted considering the treated pathology and the condition of the patient to which it is administered.
- the recommended starting dose for cancer treatment for adult patients is 125 mg once daily for 21 days followed by 7 days off treatment, along with dosing interruption and/or dose reductions based on individual safety and tolerability.
- compound (1) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with palbociclib.
- palbociclib for use in the treatment of cancer by co-administration with compound (1) or a pharmaceutically acceptable salt thereof.
- the cancer is a hormone dependent cancer.
- the cancer is an estrogen receptor dependent cancer, particularly the cancer is an estrogen receptor a dependent cancer.
- the cancer is resistant to anti-hormonal treatment.
- the cancer is a cancer with wild type estrogen receptors.
- the cancer is a cancer with deregulated function of estrogen receptors related to, but not limited to, at least one epigenetic and genetic alteration of estrogen receptors such us mutation, amplification, splice variant.
- the cancer is a cancer with mutated estrogen receptors.
- the mutations of estrogen receptors can include, but not limited to, new or known mutations such as Leu536Arg, Tyr537Ser, Tyr537Asn, or Asp538Gly.
- the cancer is an estrogen-sensitive cancer.
- the cancer is breast cancer, more particularly an estrogen receptor positive breast cancer (ER ⁇ positive breast cancer), or a metastasis thereof, such as a cerebral metastasis.
- ER ⁇ positive breast cancer estrogen receptor positive breast cancer
- metastasis thereof such as a cerebral metastasis.
- a method of treating the pathological conditions indicated above, particularly breast cancer comprising administering to a subject in need thereof a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of palbociclib.
- a method of treating the pathological conditions indicated above, particularly breast cancer comprising administering to a subject in need thereof a pharmaceutical composition as described above.
- a method of treating the pathological conditions indicated above, particularly breast cancer comprising administering to a subject in need thereof a combination as described above.
- a method of treating the pathological conditions indicated above, particularly breast cancer comprising co-administering to a subject in need thereof compound (1) or a pharmaceutically acceptable salt thereof and palbociclib.
- a method of treating the pathological conditions indicated above, particularly breast cancer comprising co-administering to a subject in need thereof palbociclib and compound (1) or a pharmaceutically acceptable salt thereof.
- the subject is a human.
- a combination comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib for the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer.
- compound (1) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with palbociclib.
- palbociclib in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with compound (1) or a pharmaceutically acceptable salt thereof.
- an article of manufacture comprising:
- liquid chromatography/mass spectra were obtained on a UPLC Acquity Waters instrument, light scattering detector Sedere and SQD Waters mass spectrometer using UV detection DAD 210 ⁇ I ⁇ 400 nm and column Acquity UPLC CSH C18 1.7 ⁇ m, dimension 2.1 ⁇ 30 mm, mobile phase H 2 O+0.1% HCO 2 H/CH 3 CN+0.1% HCO 2 H.
- the reaction mixture was stirred at room temperature for 24 hours, meanwhile a precipitate of triphenylphosphine oxide formed (Ph 3 P ⁇ O).
- the reaction mixture was poured in water (1.5 L) and extracted with ethyl acetate (AcOEt) (3 ⁇ 1.5 L). Gathered organic phases were dried over magnesium sulfate (MgSO 4 ), filtered and concentrated under reduced pressure. The residue was taken up into diisopropylether (1.5 L) and the solid formed (Ph 3 P ⁇ O) was filtered.
- reaction mixture was stirred at 60° C. for 1 hour. After cooling to room temperature, the reaction mixture was poured into a mixture of water (500 ml) and AcOEt (400 ml). The organic phase was washed with brine, dried over MgSO 4 , filtered on celite and concentrated under reduced pressure.
- the treated groups included compound (1) at 5 mg/kg alone, palbociclib at 100 mg/kg alone, and the combination of compound (1) and palbociclib at the same dose and regime.
- Compound (1) was orally dosed twice a day (BID) and palbociclib was orally dosed once a day (QD) for 30 days.
- Anti-tumor efficacy was evaluated by tumor volume measurement.
- mice Female athymic nude mice were obtained from Harlan (Indianapolis, Ind., USA). Animals were allowed to acclimate for at least four days before the study enrollment. Mice were 12 to 13 weeks old and weighed between 20.2 and 27.3 grams at the beginning of the treatments. These animals were housed under conditions outlined in the NIH Guide for Care and Use of Laboratory Animals in compliance with the USDA Laboratory Animal Welfare Act.
- MCF7-Y537S (ESR1) cell line was MCF7 cells expressing the ER.Y537S variant that was generated by Sanofi Biology Discovery Group.
- Y537S mutation was introduced in ESR1 construct (GenBank NM_000125.3) by site directed mutagenesis (Toy W. et al., Cancer Discovery, 2017, 7, 277-287). The construct was transfected in MCF7 cells which were selected for their growth in absence of estradiol.
- MCF-Y537S is an ESR1 mutation that confers estrogen-independent activity to ER ⁇ (Estrogen Receptor alpha) and contributes to endocrine resistant disease (Robinson D.
- the cells were grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS), human Insulin, in 5% CO 2 at 37° C.
- EMEM Eagle's Minimum Essential Medium
- FBS fetal bovine serum
- FBS human Insulin
- the cells were harvested in 0.25% Trypsin EDTA and washed by Dulbecco's Phosphate Buffered Saline (DPBS) and re-suspended in DPBS with 50% matrigel (Becton Dickinson catalog No. 356234, lot No. 32277).
- the cells (20 ⁇ 10 6 cells/per mouse) were subcutaneously (SC) implanted into the right flank of female nude mice.
- the tumors were reserved as tumor stocks for fragment implantation.
- the tumors were serially propagated through fragment tissue transplantation subcutaneously.
- the fragment tumor tissues were subcutaneously implanted into the right flank of female nude mice. 50 mice were assigned in this experiment.
- Compound (1) was prepared in Vehicle A, then Solutol HS15 (purchased from Sigma) was added to the final concentration 5%, and the solution was left under stirring for an hour for complete dissolution. After that, vehicle B was added. The final pH was 5.5.
- Dose volume for compound (1) administration 10 ml/kg by oral gavage.
- Palbociclib was prepared in Vehicle A, then Solutol HS15 was added to the final concentration 5%, and the solution was left under stirring for an hour for complete dissolution. After that, vehicle B was added. The final pH was 5.5.
- Dose volume 10 ml/kg by oral gavage.
- mice were pooled and randomly distributed to the treatment and control groups (10 mice per group), where median tumor volumes for each group ranged from 202.5 to 211.5 mm 3 .
- Treatments of compound (1) and palbociclib were initiated on day 22.
- Compound (1) was orally administered at 5 mg/kg BID (at least 5 hours apart) and palbociclib was orally administered at 100 mg/kg QD, for 30 days. Animal body weight was assessed daily.
- the dosages are expressed in mg/kg and based on daily body weight per animal. Vehicle treated animals were used as controls. Mice were checked daily and adverse clinical reactions noted. Individual mice were weighed daily until the end of the experiment. Mice would be euthanized when morbid or weight loss ⁇ 20% was observed. Tumors were measured with a caliper twice weekly until final sacrifice. When a tumor size reached approximately 2000 mm 3 or when there are animal health issues (40% area of a tumor ulcerated), animals would be euthanized and date of death recorded. Solid tumor volumes were estimated from two dimensional tumor measurements and calculated according to the following equation:
- Tumor ⁇ volume ⁇ ( mm 3 ) length ⁇ ( mm ) ⁇ width 2 ( mm 2 ) 2
- Examples include animal handling issues such as misgavage, tumor model related issues such as tumor induced cachexia leading to body weight loss that can be observed in control or vehicle treated groups and excessive tumor ulceration. Mice that have non-drug related death or significant bodyweight loss will not be considered toxic and will be excluded from statistical analysis. Animal body weight included the tumor weight.
- the primary efficacy end points include tumor volume changes from baseline summarized by the ratio of medians of tumor volume changes from baseline between the treated and control groups ( ⁇ T/ ⁇ C). Changes in tumor volume for each treated (T) and control (C) group are calculated for each animal on each day by subtracting the tumor volume on the day of first treatment (staging day) from the tumor volume on the specified observation day. The median ⁇ T is calculated for the treated group and the median ⁇ C is calculated for the control group. The ratio ⁇ T/ ⁇ C is calculated and expressed as percentage:
- Percent tumor regression is defined as % (percentage) of tumor volume decrease in the treated group on a specified observation day compared to its volume when the study was initiated. At a specific time point (t) and for each animal, the regression percentage is calculated using the following formula:
- the median percent regression for a group on a given day is then calculated by taking the median of individual % regression values calculated for each animal in the group.
- the day of calculation is determined by the day when ⁇ T/ ⁇ C is calculated, excepted if median percent regression is not representative of the activity of the group. In this case, the day is determined by the first day when the median percent regression is maximal.
- a two-way Anova-Type analysis with factors treatment and day (repeated) is performed on tumor volume changes from baseline. It is followed by contrast analyses with Bonferroni-Holm correction for multiplicity to compare all treated groups to the control group and to compare the combination versus each single agent at the dose involved in the combination at each day from day 27 to 51.
- Tumor volume changes from baseline are calculated for each animal and each day by subtracting the tumor volume on the day of first treatment (day 21) from the tumor volume on the specified observation day.
- FIG. 2 Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice: tumor volume evolution.
- the curves represent medians + or ⁇ MAD (Median Absolute Deviation) at each day for each group;
- FIG. 3 Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice: tumor volume changes from baseline on day 51. Points represent individual tumor volume changes from baseline on day 51, bars correspond to medians.
- NR no regression (0% regression).
- # Statistical analysis Comparison of each single agent and combination versus the control group. The p-values were obtained using a contrast analysis to compare each treated group versus control at each day using Bonferroni-Holm adjustment for multiplicity after a two-way Anova-Type with repeated measures on tumor volume changes from baseline. A probability less than 5% (p ⁇ 0.05) was considered as significant. *3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study.
- nMAD Median Absolute Deviation
- nMAD normalized MAD
- nMAD 1.4826*MAD.
- palbociclib 100 mg/kg, the effect on tumor volume changes from baseline is significant compared to the control group from day 30 to day 51.
- the combination compound (1) at 5 mg/kg + palbociclib at 100 mg/kg the effect on tumor volume changes from baseline is significant compared to the control group from day 27 to day 51.
- n number of animals. 3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study.
- nMAD Median Absolute Deviation
- nMAD normalized MAD
- nMAD 1.4826*MAD
- the effect of the combination of compound (1) at 5 mg/kg + palbociclib at 100 mg/kg is significantly greater than the effect of palbociclib at 100 mg/kg alone on day 34 to day 51.
- the effect of the combination of compound (1) at 5 mg/kg + palbociclib at 100 mg/kg is significantly greater than the effect of compound (1) at 5 mg/kg alone on day 27 to day 51.
- n number of animals. 3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study.
Abstract
Herein are provided a combination of palbociclib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.
Description
- This application is a continuation of U.S. application Ser. No. 16/634,089, filed on Jan. 24, 2020, which is a U.S. National Stage application under 35 U.S.C. § 371 of International Application No. PCT/EP2018/069901, filed on Jul. 23, 2018, which claims priority to and the benefit of U.S. Provisional Application No. 62/536,121, filed on Jul. 24, 2017, and European Application No. 17305998.1, filed on Jul. 25, 2017, the contents of each of which are hereby incorporated by reference in their entireties.
- Herein are provided a combination of palbociclib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, a pharmaceutical composition containing such a combination, and the therapeutic uses of such combination and pharmaceutical composition, in particular for the treatment of cancer.
- The estrogen receptor a (ESR1) is expressed in the majority of breast tumors, enabling them to respond to the mitogenic actions of estrogens.
- 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, hereafter designated as “compound (1)”, is a selective estrogen receptor degrader (SERD) which has complete estrogen receptor antagonist properties and accelerates the proteasomal degradation of the estrogen receptor. This compound is disclosed in the patent application PCT/EP2017/053282, published as WO 2017/140669.
- Palbociclib, also known as 6-acetyl-8-cyclopentyl-5-methyl-2-[5-(1-piperazinyl)pyridine-2-ylamino]pyrido[2,3-d]pyrimidin-7(8H)-one, is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Palbociclib is marketed under the tradename Ibrance® and is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor, or in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
- There is always a need to find new antitumoral treatments. Now, it has been shown that a combination of compound (1) with palbociclib is well tolerated, demonstrates strong anti-tumor efficacy and induces tumor regression, with a synergistic effect compared to each of the active ingredient alone.
- Herein is provided a combination comprising compound (1) and palbociclib.
-
FIG. 1 . Synthetic scheme for the synthesis of compound (1). -
FIG. 2 . Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice, showing tumor volume evolution (tumor volume in mm3 versus days of treatment). -
FIG. 3 . Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice, showing tumor volume changes from baseline onday 51 of treatment. - In the combination provided herein, compound (1) may exist not only in the form of a zwitterion (i.e. a globally neutral molecule having an acid group and a basic group), but also in the form of addition salts with acids or bases. Such addition salts may be used in the above combination. Hence, herein is provided a combination comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib.
- In an embodiment, the combination of compound (1), or a pharmaceutically acceptable salt thereof, with palbociclib shows therapeutic synergy. A combination demonstrates therapeutic synergy if its therapeutic effect is superior compared to the cumulative effect of either active agent of the combination alone.
- In another embodiment, compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib are administered by the oral route.
- Provided herein is also a combination of compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib for its use as a medicament.
- Provided herein is also a pharmaceutical composition comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib, as well as at least one pharmaceutically acceptable excipient.
- The excipients are selected from the customary excipients which are known to a person skilled in the art. More particularly, the excipients are selected from those useful for oral administration in whatever form (liquid solution, dispersion or suspension, tablets, capsules or the like).
- In another embodiment, compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib may be administered simultaneously, separately, or spaced out over a period of time (sequential administration). Therefore, the combination provided herein is not exclusively limited to the one which is obtained by physical association of the constituents in a single pharmaceutical composition, but also to those which allow a separate administration, which can be simultaneous or spaced out (or “spread out”) over time.
- Herein is also provided a pharmaceutical kit which comprises:
-
- (i) a first pharmaceutical composition comprising compound (1), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
- (ii) a second pharmaceutical composition comprising palbociclib, and at least one pharmaceutically acceptable excipient;
- both pharmaceutical compositions (i) and (ii) being in separate compartments and being intended to be independently administered, each administration with regards to the other one being simultaneous, separated or spread out (sequential) overtime.
- In the combinations, pharmaceutical compositions and pharmaceutical kit described above, the compound (1) or pharmaceutically acceptable salt thereof and palbociclib are advantageously present at effective doses, adapted considering the treated pathology and the condition of the patient to which it is administered. In particular for palbociclib, the recommended starting dose for cancer treatment for adult patients is 125 mg once daily for 21 days followed by 7 days off treatment, along with dosing interruption and/or dose reductions based on individual safety and tolerability.
- Herein is also provided a combination comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib, as well as a pharmaceutical composition and kit as described above, for use in the treatment of cancer.
- Herein is also provided compound (1) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with palbociclib.
- Herein is also provided palbociclib for use in the treatment of cancer by co-administration with compound (1) or a pharmaceutically acceptable salt thereof.
- In another embodiment, the cancer is a hormone dependent cancer.
- In another embodiment, the cancer is an estrogen receptor dependent cancer, particularly the cancer is an estrogen receptor a dependent cancer.
- In another embodiment, the cancer is resistant to anti-hormonal treatment.
- In another embodiment, the cancer is a cancer with wild type estrogen receptors.
- In another embodiment, the cancer is a cancer with deregulated function of estrogen receptors related to, but not limited to, at least one epigenetic and genetic alteration of estrogen receptors such us mutation, amplification, splice variant.
- In another embodiment, the cancer is a cancer with mutated estrogen receptors.
- In another embodiment, the mutations of estrogen receptors can include, but not limited to, new or known mutations such as Leu536Arg, Tyr537Ser, Tyr537Asn, or Asp538Gly.
- In another embodiment, the cancer is an estrogen-sensitive cancer.
- In another embodiment, the cancer is breast cancer, more particularly an estrogen receptor positive breast cancer (ERα positive breast cancer), or a metastasis thereof, such as a cerebral metastasis.
- Herein is also provided a method of treating the pathological conditions indicated above, particularly breast cancer, comprising administering to a subject in need thereof a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of palbociclib.
- Herein is also provided a method of treating the pathological conditions indicated above, particularly breast cancer, comprising administering to a subject in need thereof a pharmaceutical composition as described above.
- Herein is also provided a method of treating the pathological conditions indicated above, particularly breast cancer, comprising administering to a subject in need thereof a combination as described above.
- Herein is also provided a method of treating the pathological conditions indicated above, particularly breast cancer, comprising co-administering to a subject in need thereof compound (1) or a pharmaceutically acceptable salt thereof and palbociclib.
- Herein is also provided a method of treating the pathological conditions indicated above, particularly breast cancer, comprising co-administering to a subject in need thereof palbociclib and compound (1) or a pharmaceutically acceptable salt thereof.
- In an embodiment of the methods described above, the subject is a human.
- Herein is also provided a combination comprising compound (1), or a pharmaceutically acceptable salt thereof, and palbociclib for the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer.
- Herein is also provided the use of compound (1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with palbociclib.
- Herein is also provided the use of palbociclib in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with compound (1) or a pharmaceutically acceptable salt thereof.
- Herein is also provided an article of manufacture, a packaging, or an administration unit, comprising:
-
- a packaging material;
- the above defined combination, pharmaceutical composition or pharmaceutical kit; and
- a label or package insert contained within said packaging material, indicating that said combination, pharmaceutical composition or pharmaceutical kit is administered to a patient for the treatment of cancer.
- The examples below show how to synthesize compound (1), and the pharmacological results obtained with compound (1), palbociclib and their combination against a breast cancer cell line xenograft in mice.
- The experimental protocol for synthesizing 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (compound (1)), described in the patent application WO 2017/140669, is reproduced below, along with its analytical data. The synthetic scheme for the synthesis of compound (1) is found in
FIG. 1 . - The 1H NMR spectra were performed on a Bruker Avance DRX-400 spectrometer, with the chemical shifts (δ in ppm) in the solvent dimethyl sulfoxide-d6 (d6-DMSO) referenced at 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in Hertz.
- The liquid chromatography/mass spectra (LC/MS) were obtained on a UPLC Acquity Waters instrument, light scattering detector Sedere and SQD Waters mass spectrometer using UV detection DAD 210<I<400 nm and column Acquity UPLC CSH C18 1.7 μm, dimension 2.1×30 mm, mobile phase H2O+0.1% HCO2H/CH3CN+0.1% HCO2H.
- The following abbreviations and empirical formulae are used:
- AcOEt ethyl acetate
- AlCl3 aluminium trichloride
- Cs2CO3 cesium carbonate
- DCM dichloromethane
- DMF N,N-dimethylformamide
- DMSO dimethyl sulfoxide
- HCl hydrogen chloride
- K2CO3 potassium carbonate
- LC/MS liquid chromatography/mass spectrometry
- MeOH methanol
- MgSO4 magnesium sulfate
- NaHCO3 sodium bicarbonate
- NaOH sodium hydroxyde
- Pd(dppf)
Cl - Ph3P or P(Ph)3 triphenylphosphine
- Ph3P═O triphenylphosphine oxide
- ° C. degrees Celsius
- ml millilitre(s)
- mmol millimole(s)
- μmol micromole(s)
- μM micromolar
- nM nanomolar
- ppm parts per million
-
- To a solution of commercially available 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (a) (82.7 g, 364.51 mmol) in THF (2 L) was added under argon (R)-1-N-Boc-3-hydroxypyrrolidine (b) (84.43 g, 437.41 mmol) followed by N,N,N′,N′-tetramethylazodicarboxamide (99.1 g, 546.77 mmol). The clear reaction mixture turned orange and triphenylphosphine (143.41 g, 546.77 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours, meanwhile a precipitate of triphenylphosphine oxide formed (Ph3P═O). The reaction mixture was poured in water (1.5 L) and extracted with ethyl acetate (AcOEt) (3×1.5 L). Gathered organic phases were dried over magnesium sulfate (MgSO4), filtered and concentrated under reduced pressure. The residue was taken up into diisopropylether (1.5 L) and the solid formed (Ph3P═O) was filtered. The solvent was concentrated under reduced pressure and the residue purified by column chromatography eluting with a mixture of heptane with AcOEt (90/10; v/v) to give 145 g (100%) of tert-butyl (3S)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine-1-carboxylate (c) as a colorless oil.
- 1H NMR (400 MHz, DMSO-d6, δ ppm): 1.27 (s: 12H); 1.39 (s: 9H); 2.05 (m: 1H); 2.14 (m: 1H); 3.37 (3H); 3.55 (m: 1H); 5.05 (s: 1H); 6.94 (d, J=8.4 Hz: 2H); 7.61 (d, J=8.4 Hz: 2H)
-
- To a solution of (S)-tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine-1-carboxylate (c) (80 g, 195.23 mmol) in MeOH (450 ml) was added slowly HCl 4N in dioxane (250 ml).
- After 1.5 hours, the reaction mixture was concentrated under reduced pressure and the residue was taken up into Et2O with stirring to give a solid which then was filtered and dried under vacuum to give 61.8 g (95%) of (3S)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy]pyrrolidine, hydrochloride (d) as a white powder.
- 1H NMR (400 MHz, DMSO-d6, δ ppm): 1.28 (s: 12H); 2.10 (m: 1H); 2.21 (m: 1H); 3.31 (3H); 3.48 (m: 1H); 5.19 (m: 1H); 6.97 (d, J=8.4 Hz: 2H); 7.63 (d, J=8.4 Hz: 2H); 9.48 (s: 1H); 9.71 (s: 1H).
- LC/MS (m/z, MH+): 290
-
- To a suspension of (S)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine hydrochloride (d) (20 g, 61.42 mmol) in acetonitrile (100 ml), was added K2CO3 (21.22 g, 153.54 mmol) and 1-iodo-3-fluoropropane (12.15 g, 61.42 mmol), under argon. The reaction mixture was stirred at 40° C. for 24 hours. After cooling to room temperature, the reaction mixture was filtered and washed with acetonitrile. The filtrate was concentrated under reduced pressure and the residue was taken up in DCM and the solid formed was filtered and washed with DCM. The filtrate was concentrated to give 21.5 g (100%) of (3S)-1-(3-fluoropropyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (e) as a yellow foam.
- 1H NMR (400 MHz, DMSO-d6, δ ppm): 1.27 (s: 12H); 1.77 (m: 2H); 1.84 (m: 1H); 2.27 (m: 1H); 2.41 (m: 1H); 2.49 (2H); 2.62 (dd, J=2.6 and 10.4 Hz: 1H); 2.69 (m: 1H); 2.83 (dd, J=6.2 and 10.4 Hz: 1H); 4.47 (td, J=6.2 and 47 Hz: 2H); 4.99 (m: 1H); 6.77 (d, J=8.4 Hz: 2H); 7.58 (d, J=8.4 Hz: 2H).
- LC/MS (m/z, MH+): 350
-
- To a solution of 2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (A) (1.52 g, 8.63 mmol), in acetone (60 ml), was added K2CO3 (1.19 g, 8.63 mmol) and pivaloyl chloride (1.06 ml, 8.63 mmol). The reaction mixture was stirred at room temperature for 16 hours, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane in AcOEt (100/0 to 85/15, v/v) to give 1.55 g (69%) of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-
yl 2,2-dimethylpropanoate (B) as a colorless oil. - 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.65 (d, 1H); 7.10-7.04 (m, 2H); 2.95 (t, 2H); 2.68 (t, 2H); 1.85-1.65 (m, 4H).
- LC/MS (m/z, MH+): 261
-
- To a solution of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-
yl 2,2-dimethylpropanoate (B) (15 g, 57.62 mmol) in DCM (500 ml) was added dropwise under argon pyridine (7.28 ml, 86.43 mmol) and trifluoromethanesulfonic anhydride (19.58 ml, 115.24 mmol). The reaction mixture was stirred at room temperature for 2 hours and ice (200 g) was added. The phases were separated, the aqueous phase was washed with DCM and the gathered organic phases were dried over MgSO4, filtered and evaporated under reduced pressure to give 22 g (97%) of 9-(trifluoromethanesulfonyloxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl 2,2-dimethylpropanoate (C) as a white solid. - LC/MS (m/z, MH−): 391
-
- To a solution of 9-(trifluoromethanesulfonyloxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (C) (22 g, 56.07 mmol) and (3S)-1-(3-fluoropropyl)-3-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (e) (20.56 g, 58.87 mmol) in dioxane (420 ml) and water (120 ml) was added under argon Pd(dppf)Cl2 (2.75 g, 3.36 mmol) and Cs2CO3 (36.57 g, 112.13 mmol). The reaction mixture was stirred for 1 hour at room temperature and was partitioned between water and DCM. The aqueous phase was washed with DCM and the gathered organic phases dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluting with a gradient of MeOH in DCM (0 to 5%; V/V) to give 31 g (100%) of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (D).
- LC/MS (m/z, MH+): 466
-
- To a solution under argon of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (D) (24.8 g, 53.26 mmol) in MeOH (300 ml), was added NaOH 5M (23 ml, 115.00 mmol). The reaction mixture was stirred for 2 hours at room temperature. pH was then adjusted to 7 by addition of 6N aqueous HCl solution. The MeOH was concentrated under reduced pressure, then DCM was added. The organic phase was dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/0 to 95/05 to give 18.8 g (93%) of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol (E) as a beige solid.
- LC/MS (m/z, MH+): 382
-
- To a solution of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol (E) (20.6 g, 54.00 mmol) in DCM (200 ml) and pyridine (6.55 ml, 81.00 mmol), cooled to 5° C. (ice bath), was added dropwise trifluoromethanesulfonic anhydride (18.93 ml, 108.00 mmol) under argon, and the reaction temperature was maintained <15° C. The ice bath was removed, and the brown suspension was stirred at room temperature for 2 hours. Ice (200 g) and DCM (200 ml) were added and the phases separated. The organic phase was dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/0 to 95/05 to give 24.7 g (89.1%) of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl trifluoromethanesulfonate (F) as a brown oil.
- LC/MS (m/z, MH+): 514
-
- To a solution of 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl trifluoromethanesulfonate (F) (10.1 g, 19.67 mmol) in DMF (66 ml) and MeOH (33 ml), were added Pd(dppf)Cl2 (909 mg, 1.18 mmol) and diisopropylethylamine (7.21 ml). The black suspension was carbonylated in an autoclave at 70° C. under 5 bars of CO for 5 hours. The reaction mixture was filtered, then the filtrate was partially concentrated under reduced pressure. The residue was partitioned between AcOEt and water. The organic phase was washed with water (2×100 ml), dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/0 to 95/05 to give 7.13 g (86%) of methyl 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (G) as a brown gum.
- LC/MS (m/z, MH+): 424
-
- To a solution of commercially available 2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (A) (18.5 g, 105 mmol) in DCM (185 ml) and lutidine (13.35 ml, 113.505 mmol), cooled at 5° C. under argon, was added dropwise trifluoromethanesulfonic anhydride (20.22 ml, 123.29 mmol) while keeping temperature between 10 and 20° C. The reaction mixture was stirred for 1 hour at 5° C. then at room temperature for 1 hour.
- Then, ice (200 g) was added and the slurry partitioned between water and DCM. The organic phase was washed with aqueous NaHCO3 solution, dried over MgSO4, filtered off and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane/AcOEt from 100 to 90/10 to give 28.2 g (87%) of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl trifluoromethanesulfonate (A1) as an orange oil.
- LC/MS (m/z, MH+): 309
-
- To a solution of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl trifluoromethanesulfonate (A1) (5.03 g, 16.32 mmol) in DMF (24 ml) and MeOH (12 ml), were added Pd(dppf)Cl2 (754 mg, 0.98 mmol) and diisopropylethylamine (6 ml). The black suspension was carbonylated in an autoclave at 70° C. under 5 bars of CO for 2.5 hours. The reaction mixture was filtered, then the filtrate was partially concentrated under reduced pressure, and the residue, was partitioned between AcOEt and water. The organic phase was washed with water (2×75 ml) and aqueous HCl 0.5 N, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane/AcOEt from 100/0 to 90/10 to give 3.4 g (95%) of methyl 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate (B1) as a colorless oil.
- LC/MS (m/z, MH+): 219
-
- To a solution of methyl 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate (B1) (18.19 g, 83.34 mmol) in DCM (500 ml) and anhydrous pyridine (11 ml, 130.56 mmol), cooled at 5° C. under argon, was added dropwise trifluoromethanesulfonic anhydride (30 ml, 176.54 mmol). The reaction mixture, a thick suspension, was stirred at room temperature for 24 hours, then ice was added and partitioned between water and DCM. The organic phase was dried over MgSO4, filtered off and concentrated under reduced pressure to give 29 g (100%) of methyl 9-(trifluoromethanesulfonyloxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (C1) as a yellow gum.
- LC/MS (m/z, MH+): 351
-
- To a solution of methyl 9-(trifluoromethanesulfonyloxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (C1) (29 g, 82.9 mmol), (3S)-1-(3-fluoropropyl)-3-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (e) (28.9 g, 82.9 mmol), in dioxane (225 ml) were added Pd(dppf)Cl2 under argon, complex with DCM (3.73 g, 4.57 mmol) and Cs2CO3 1.5 M aqueous solution (111.12 ml, 166.68 mmol). The reaction mixture was stirred at 60° C. for 1 hour. After cooling to room temperature, the reaction mixture was poured into a mixture of water (500 ml) and AcOEt (400 ml). The organic phase was washed with brine, dried over MgSO4, filtered on celite and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/0 to 95/05 to give 23 g (65%) of methyl 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (G) as a brown gum.
- LC/MS (m/z, MH+): 424
-
- To a solution of methyl 9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (G) (13.93 g, 32.89 mmol), in DCM (150 ml) was added under argon pyridinium tribromide (15.78 g, 44.41 mmol). The reaction mixture was stirred for 1 hour at room temperature. Water (200 ml) was added, organic phase was then dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/0 to 95/05 to give 16.4 g (85%) of methyl 8-bromo-9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate hydrobromide (H) as a yellow meringue.
- LC/MS (m/z, MH+): 502
-
- To a solution of methyl 8-bromo-9-(4-{[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate hydrobromide (H) (150 mg, 298.56 μmol), in dioxane (12 ml) and water (2 ml), was added 2,4-dichlorophenyl-boronic acid (62.67 mg, 328.41 μmol), Cs2CO3 (204.48 mg, 626.97 μmol), and Pd(dppf)Cl2 (14.63 mg, 17.91 μmol). The reaction mixture was heated at 90° C. for 3 hours, and partitioned between AcOEt and water. The phases were separated and the organic phase washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by column chromatography eluting with a mixture of DCM, acetonitrile and MeOH (96/2/2; V/V/V) to give 80 mg (47%) of 6-(2,4-dichloro-phenyl)-5-{4-[1-(3-fluoro-propyl)-pyrrolidin-3-yloxy]-phenyl}-8,9-dihydro-7H-benzocycloheptene-2-carboxylic acid methyl ester (I).
- LC/MS (m/z, MH+): 568
-
- To a solution of 6-(2,4-dichloro-phenyl)-5-{4-[1-(3-fluoro-propyl)-pyrrolidin-3-yloxy]-phenyl}-8,9-dihydro-7H-benzocycloheptene-2-carboxylic acid methyl ester (I) (80 mg, 140.72 μmol) in MeOH (5 ml) was added a solution of NaOH (562.88 μl, 5 M) and the reaction mixture was heated at 60° C. for 5 hours and the solvent removed under reduced pressure. The residue was taken up in water (10 ml) and aqueous HCl (5 M) added to
pH 7. The slurry was extracted with DCM, dried over MgSO4 and concentrated under reduced pressure. The solid was purified by column chromatography eluting with a mixture of DCM, acetonitrile and MeOH (90/5/5; V/V/V) to give 60 mg (77%) of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid. - 1H NMR (400 MHz, DMSO-d6, δ ppm): 1.68 (m, 1H); 1.79 (dm, J=25.3 Hz, 2H); 2.07 to 2.23 (m, 5H); 2.38 (m, 1H); 2.46 (t, J=7.2 Hz, 2H); 2.52 (m, 1H); 2.62 (m, 1H); 2.55 to 2.89 (m, 3H); 4.47 (td, J=6.2 and 47.6 Hz, 2H); 4.72 (m, 1H); 6.63 (d, J=8.9 Hz, 2H); 6.71 (m, 3H); 7.18 (d, J=8.4 Hz, 1H); 8.26 (dd, J=2.0 and 8.4 Hz, 1H); 7.58 (d, J=2.0 Hz, 1H); 7.63 (d, J=8.4 Hz, 1H); 7.79 (s, 1H); 12.3 (m, 1H)
- LC/MS (m/z, MH+): 554
- In the present study, the anti-tumor efficacy of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (“compound (1)”), combined with the cyclin-dependent kinase 4 (CDK4) inhibitor palbociclib, was investigated after 30 days treatment against a subcutaneous MCF7-Y537S human breast cancer cell line xenograft in female nude mice.
- The treated groups included compound (1) at 5 mg/kg alone, palbociclib at 100 mg/kg alone, and the combination of compound (1) and palbociclib at the same dose and regime.
- Compound (1) was orally dosed twice a day (BID) and palbociclib was orally dosed once a day (QD) for 30 days. Anti-tumor efficacy was evaluated by tumor volume measurement.
- 2-1: Experimental Procedure
- 2-1-1: Animals, Cell Line, Compounds
- Female athymic nude mice were obtained from Harlan (Indianapolis, Ind., USA). Animals were allowed to acclimate for at least four days before the study enrollment. Mice were 12 to 13 weeks old and weighed between 20.2 and 27.3 grams at the beginning of the treatments. These animals were housed under conditions outlined in the NIH Guide for Care and Use of Laboratory Animals in compliance with the USDA Laboratory Animal Welfare Act.
- Parental MCF7 cells were obtained from the American Type Culture Collection (ATCC® HTB-22™). MCF7-Y537S (ESR1) cell line was MCF7 cells expressing the ER.Y537S variant that was generated by Sanofi Biology Discovery Group. Y537S mutation was introduced in ESR1 construct (GenBank NM_000125.3) by site directed mutagenesis (Toy W. et al., Cancer Discovery, 2017, 7, 277-287). The construct was transfected in MCF7 cells which were selected for their growth in absence of estradiol. MCF-Y537S is an ESR1 mutation that confers estrogen-independent activity to ERα (Estrogen Receptor alpha) and contributes to endocrine resistant disease (Robinson D. R. et al., Nat Genet., 2013, 45 (12), 1446-1451). The cells were grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS), human Insulin, in 5% CO2 at 37° C. The cells were harvested in 0.25% Trypsin EDTA and washed by Dulbecco's Phosphate Buffered Saline (DPBS) and re-suspended in DPBS with 50% matrigel (Becton Dickinson catalog No. 356234, lot No. 32277). The cells (20×106 cells/per mouse) were subcutaneously (SC) implanted into the right flank of female nude mice.
- When the MCF7-Y537S tumors were established, the tumors were reserved as tumor stocks for fragment implantation. The tumors were serially propagated through fragment tissue transplantation subcutaneously. The fragment tumor tissues were subcutaneously implanted into the right flank of female nude mice. 50 mice were assigned in this experiment.
- Compound (1) and palbociclib (commercially available, marketed under the tradename Ibrance®) were formulated as follows:
-
- Vehicle A: 20% Labrasol® (supplied from Gattefosse SAS, France);
- Vehicle B: 5% Dextrose.
- Compound (1) was prepared in Vehicle A, then Solutol HS15 (purchased from Sigma) was added to the
final concentration 5%, and the solution was left under stirring for an hour for complete dissolution. After that, vehicle B was added. The final pH was 5.5. - Dose volume for compound (1) administration: 10 ml/kg by oral gavage.
- Doses: 5 mg/kg (dosage of compound (1) in the above volume).
- Palbociclib was prepared in Vehicle A, then Solutol HS15 was added to the
final concentration 5%, and the solution was left under stirring for an hour for complete dissolution. After that, vehicle B was added. The final pH was 5.5. - Dose volume: 10 ml/kg by oral gavage.
- Doses: 100 mg/kg (dosage of palbociclib in the above volume).
- 2-1-2: Study Design, End Points
- The animals required for experiment (plus extra) were pooled and implanted with MCF7-Y537S tumor fragment tissues on
day 0. Onday 21 post implantation, the mice were pooled and randomly distributed to the treatment and control groups (10 mice per group), where median tumor volumes for each group ranged from 202.5 to 211.5 mm3. Treatments of compound (1) and palbociclib were initiated on day 22. Compound (1) was orally administered at 5 mg/kg BID (at least 5 hours apart) and palbociclib was orally administered at 100 mg/kg QD, for 30 days. Animal body weight was assessed daily. - The dosages are expressed in mg/kg and based on daily body weight per animal. Vehicle treated animals were used as controls. Mice were checked daily and adverse clinical reactions noted. Individual mice were weighed daily until the end of the experiment. Mice would be euthanized when morbid or weight loss ≥20% was observed. Tumors were measured with a caliper twice weekly until final sacrifice. When a tumor size reached approximately 2000 mm3 or when there are animal health issues (40% area of a tumor ulcerated), animals would be euthanized and date of death recorded. Solid tumor volumes were estimated from two dimensional tumor measurements and calculated according to the following equation:
-
- Toxicity End Points:
- A dosage producing either 15% body weight loss during 3 consecutive days for an individual mouse, 20% body weight loss during 1 day, or 10% or more drug related deaths, was considered an excessively toxic dosage, unless under certain circumstances bodyweight loss or animal death can be considered non-drug related. Examples include animal handling issues such as misgavage, tumor model related issues such as tumor induced cachexia leading to body weight loss that can be observed in control or vehicle treated groups and excessive tumor ulceration. Mice that have non-drug related death or significant bodyweight loss will not be considered toxic and will be excluded from statistical analysis. Animal body weight included the tumor weight.
- Efficacy End Points:
- The primary efficacy end points include tumor volume changes from baseline summarized by the ratio of medians of tumor volume changes from baseline between the treated and control groups (ΔT/ΔC). Changes in tumor volume for each treated (T) and control (C) group are calculated for each animal on each day by subtracting the tumor volume on the day of first treatment (staging day) from the tumor volume on the specified observation day. The median ΔT is calculated for the treated group and the median ΔC is calculated for the control group. The ratio ΔT/ΔC is calculated and expressed as percentage:
-
- ΔT/ΔC≤40% is considered as therapeutically active, ΔT/ΔC=0% is considered as tumor stasis, and ΔT/ΔC<0% is considered as tumor regression (very active). ΔT/ΔC>40% is considered as therapeutically inactive.
- Percent tumor regression is defined as % (percentage) of tumor volume decrease in the treated group on a specified observation day compared to its volume when the study was initiated. At a specific time point (t) and for each animal, the regression percentage is calculated using the following formula:
-
- The median percent regression for a group on a given day is then calculated by taking the median of individual % regression values calculated for each animal in the group. The day of calculation is determined by the day when ΔT/ΔC is calculated, excepted if median percent regression is not representative of the activity of the group. In this case, the day is determined by the first day when the median percent regression is maximal.
- 2-1-3: Statistical Analysis
- A two-way Anova-Type analysis with factors treatment and day (repeated) is performed on tumor volume changes from baseline. It is followed by contrast analyses with Bonferroni-Holm correction for multiplicity to compare all treated groups to the control group and to compare the combination versus each single agent at the dose involved in the combination at each day from
day 27 to 51. - In the figures, the medians and Median Absolute Deviation (MAD) of each group are represented for each day of measurement.
- In the tables, the medians and Normalized MAD (nMAD=1.4826*MAD) of each group are reported for each day of measurement.
- Tumor volume changes from baseline are calculated for each animal and each day by subtracting the tumor volume on the day of first treatment (day 21) from the tumor volume on the specified observation day.
- All statistical analyses were performed using SAS version 9.2 software. A probability of less than 5% (p<0.05) was considered as significant.
- 2-2: Results
- Compound (1) at 5 mg/kg BID, palbociclib 100 mg/kg QD and the combination of compound (1) and palbociclib at the doses and regime for 30 days were well tolerated in this study showing average body weight change in % per group at nadir (the lowest of body weight drop in the group) of −1.7% (day 22), −2.0% (day 22) and −6.4% (day 26), respectively (Table 1).
- Compound (1) at a dose of 5 mg/kg BID for 30 days had minimal effect on tumor growth with ΔT/ΔC value of 59% (p=0.4113) on
day 51. Palbociclib at a dose of 100 mg/kg QD for 30 days achieved anti-tumor efficacy with ΔT/ΔC value of 27% (p<0.0001) onday 51. When compound (1) at 5 mg/kg combined withpalbociclib 100 mg/kg with the same dose regime as BID for compound (1) and QD for palbociclib, the combination treatment demonstrated strong anti-tumor efficacy with ΔT/ΔC value less than 0 (p<0.0001) and induced tumor regression (median tumor regression 32%) onday 51. The statistical analysis indicated the combination effect was significantly different when compared to either compound (1) alone or palbociclib alone on day 51 (p<0.0001). Detailed results are shown in Tables 1, 2 and 3 below, as well as inFIGS. 2 and 3 : -
FIG. 2 : Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice: tumor volume evolution. The curves represent medians + or − MAD (Median Absolute Deviation) at each day for each group; -
FIG. 3 : Antitumor activity of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft in nude mice: tumor volume changes from baseline onday 51. Points represent individual tumor volume changes from baseline onday 51, bars correspond to medians. - From this experiment, we conclude that the compound (1) at 5 mg/kg twice a day combined with the CDK4 inhibitor palbociclib at 100 mg/kg once a day induced significant anti-tumor efficacy and tumor regression in MCF7-Y537S human breast cancer cell line xenograft model in nude mice that was superior to single agents alone.
-
TABLE 1 Efficacy of compound (1) combined with palbociclib against subcutaneous MCF7-Y537S human breast cancer xenograft in nude mice. Dosage in Schedule Average body weight Route/Dosage mg/kg per in days *Unscheduled change in % per (in mL/kg per injection (total of death group at nadir Agent injection) (total dose) 30 days) (Day of death) (day of nadir) Vehicle PO, BID (10) — — 0/10 −2.2 (22) Compound PO, BID (10) 5 (295) N.B. 22 to 51 2/10 −1.7 (22) (1) Palbociclib PO, QD (10) 100 (3000) 22 to 51 0/10 −2.0 (22) Compound PO, BID (10) 5 (295) N.B. + 22 to 51 1/10 −2.3 (26) (1) + PO, QD (10) 100 (3000) Palbociclib Median % of ΔT/ΔC in % regressions Regressions p-value on Biological Agent at day 51 on day 51 Partial Complete day 47 # Interpretation Vehicle 100 — 0/10 0/10 — — Compound 59 NR 0/8 0/8 p = 0.4113 Inactive (1) Palbociclib 27 NR 0/10 0/10 p < 0.0001 Active Compound <0 32 2/9 0/9 p < 0.0001 Very active (1) + Palbociclib PO: per os N.B.: animals accepted one dose in the starting date. NR: no regression (0% regression). # Statistical analysis: Comparison of each single agent and combination versus the control group. The p-values were obtained using a contrast analysis to compare each treated group versus control at each day using Bonferroni-Holm adjustment for multiplicity after a two-way Anova-Type with repeated measures on tumor volume changes from baseline. A probability less than 5% (p < 0.05) was considered as significant. *3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study. -
TABLE 2 Efficacy of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft model in nude mice. Comparison of each group to the control group at each day. Tumor volume changes from baseline mm3: Median (nMAD)*, n and p-value# Treatment Group Global Day 27 Day 30 Day 34 Day 37 Day 41 Day 44 Day 49 Day 51 Control — 111.5 181.0 296.0 392.0 663.0 867.0 1140.0 1322.0 (44.48) (78.58) (133.43) (235.73) (363.24) (456.64) (615.28) (633.07) n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 Compound — 114.0 171.5 270.5 336.0 440.0 498.5 727.5 782.0 (1) 5 (19.27) (31.13) (112.68) (112.68) (39.29) (91.18) (160.86) (112.68) mg/kg n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 0.3975 0.6333 0.3909 0.7343 0.5990 0.2495 0.1950 0.3770 0.4113 Palbociclib — 68.5 98.0 121.5 132.0 193.5 249.5 298.5 363.5 100 mg/kg (31.88) (25.20) (34.10) (31.88) (52.63) (43.74) (97.11) (108.23) n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 <0.0001 0.1164 0.0009 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 Compound — −8.0 −17.0 −35.0 −30.0 −43.0 −63.0 −53.0 −52.0 (1) 5 mg/kg + (63.75) (97.85) (74.13) (57.82) (60.79) (45.96) (72.65) (72.65) Palbociclib n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 100 mg/kg <0.0001 0.0077 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 #p-values obtained with a contrast analysis versus control at each day with Bonferroni-Holm adjustment for multiplicity after a two-way Anova-Type on tumor volume changes from baseline. *MAD = Median Absolute Deviation; nMAD = normalized MAD; nMAD = 1.4826*MAD. For palbociclib at 100 mg/kg, the effect on tumor volume changes from baseline is significant compared to the control group from day 30 today 51.For the combination compound (1) at 5 mg/kg + palbociclib at 100 mg/kg, the effect on tumor volume changes from baseline is significant compared to the control group from day 27 today 51.n = number of animals. 3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study. -
TABLE 3 Efficacy of compound (1) combined with palbociclib against subcutaneous human breast cancer cell line MCF7-Y537S xenograft model in nude mice. Comparison of compound (1) 5 mg/kg and palbociclib 100 mg/kg as single agents versus the combination at each day.Tumor volume changes from baseline mm3: Median (nMAD)*, n and p-value# Treatment Group Global Day 27 Day 30 Day 34 Day 37 Day 41 Day 44 Day 49 Day 51 Compound — −8.0 −17.0 −35.0 −30.0 −43.0 −63.0 −53.0 −52.0 (1) 5 mg/kg + (63.75) (97.85) (74.13) (57.82) (60.79) (45.96) (72.65) (72.65) Palbociclib n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 100 mg/kg Palbociclib — 68.5 98.0 121.5 132.0 193.5 249.5 298.5 363.5 100 mg/kg (31.88) (25.20) (34.10) (31.88) (52.63) (43.74) (97.11) (108.23) n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 <0.0001 0.2417 0.0736 0.0026 0.0002 <0.0001 <0.0001 <0.0001 <0.0001 Compound — 114.0 171.5 270.5 336.0 440.0 498.5 727.5 782.0 (1) 5 mg/kg (19.27) (31.13) (112.68) (112.68) (39.29) (91.18) (160.86) (112.68) n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 <0.0001 0.0342 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 #p-values obtained with a contrast analysis to compare the combinations of compound (1) and palbociclib versus each single agent at the dose involved in the combination at each day with Bonferroni-Holm adjustment for multiplicity after a two-way Anova-Type on tumor volume changes from baseline. *MAD = Median Absolute Deviation; nMAD = normalized MAD; nMAD = 1.4826*MAD The effect of the combination of compound (1) at 5 mg/kg + palbociclib at 100 mg/kg is significantly greater than the effect of palbociclib at 100 mg/kg alone on day 34 today 51.The effect of the combination of compound (1) at 5 mg/kg + palbociclib at 100 mg/kg is significantly greater than the effect of compound (1) at 5 mg/kg alone on day 27 today 51.n = number of animals. 3 mice were excluded from statistical analysis because those mice corresponded to non-drug related death or terminations during the study.
Claims (11)
1. A combination comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and palbociclib.
2. The combination according to claim 1 , showing therapeutic synergy.
3. The combination according to claim 1 , for use in the treatment of cancer.
4. The combination according to claim 3 , wherein the cancer is breast cancer.
5. A pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and palbociclib, and at least one pharmaceutically acceptable excipient.
6. The pharmaceutical composition according to claim 5 , wherein 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and palbociclib are administered simultaneously, separately, or spaced out over a period of time.
7. The pharmaceutical composition according to claim 5 , for use in the treatment of cancer.
8. The pharmaceutical composition according to claim 7 , wherein the cancer is breast cancer.
9. (canceled)
10. (canceled)
11. A pharmaceutical kit comprising:
(i) a first pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
(ii) a second pharmaceutical composition comprising palbociclib, and at least one pharmaceutically acceptable excipient;
both pharmaceutical compositions (i) and (ii) being in separate compartments and being intended to be independently administered, each administration with regards to the other one being simultaneous, separated or spread out over time.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/579,187 US20220362248A1 (en) | 2017-07-24 | 2022-01-19 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762536121P | 2017-07-24 | 2017-07-24 | |
EP17305998.1A EP3434272A1 (en) | 2017-07-25 | 2017-07-25 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
EP17305998.1 | 2017-07-25 | ||
PCT/EP2018/069901 WO2019020559A1 (en) | 2017-07-24 | 2018-07-23 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
US202016634089A | 2020-01-24 | 2020-01-24 | |
US17/579,187 US20220362248A1 (en) | 2017-07-24 | 2022-01-19 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/069901 Continuation WO2019020559A1 (en) | 2017-07-24 | 2018-07-23 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
US16/634,089 Continuation US11260057B2 (en) | 2017-07-24 | 2018-07-23 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220362248A1 true US20220362248A1 (en) | 2022-11-17 |
Family
ID=59569252
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/634,089 Active 2038-09-03 US11260057B2 (en) | 2017-07-24 | 2018-07-23 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
US17/579,187 Pending US20220362248A1 (en) | 2017-07-24 | 2022-01-19 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/634,089 Active 2038-09-03 US11260057B2 (en) | 2017-07-24 | 2018-07-23 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Country Status (29)
Country | Link |
---|---|
US (2) | US11260057B2 (en) |
EP (2) | EP3434272A1 (en) |
JP (1) | JP6741897B1 (en) |
KR (1) | KR20200031622A (en) |
CN (1) | CN111107851B (en) |
AR (1) | AR112284A1 (en) |
AU (1) | AU2018308871A1 (en) |
BR (1) | BR112020001398A2 (en) |
CA (1) | CA3070754A1 (en) |
CO (1) | CO2020000240A2 (en) |
DK (1) | DK3658147T3 (en) |
ES (1) | ES2906279T3 (en) |
HR (1) | HRP20212030T1 (en) |
HU (1) | HUE057271T2 (en) |
IL (1) | IL272166B2 (en) |
LT (1) | LT3658147T (en) |
MA (1) | MA49673B1 (en) |
MY (1) | MY195271A (en) |
PH (1) | PH12020500091A1 (en) |
PL (1) | PL3658147T3 (en) |
PT (1) | PT3658147T (en) |
RS (1) | RS62837B1 (en) |
RU (1) | RU2764116C2 (en) |
SG (1) | SG11202000367RA (en) |
SI (1) | SI3658147T1 (en) |
TW (1) | TWI768087B (en) |
UY (1) | UY37818A (en) |
WO (1) | WO2019020559A1 (en) |
ZA (1) | ZA202000145B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11713296B2 (en) | 2018-09-07 | 2023-08-01 | Sanofi | Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-l-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate and preparation process thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
MX2021013711A (en) * | 2019-05-09 | 2021-12-10 | Sanofi Sa | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3 -yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients. |
JP2023504912A (en) * | 2019-12-09 | 2023-02-07 | サノフイ | Crystal forms of 7H-benzo[7]annulene-2-carboxylic acid derivatives |
TW202146007A (en) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
CA3199466A1 (en) * | 2020-11-23 | 2022-05-27 | Monsif Bouaboula | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
TW202302084A (en) * | 2021-03-02 | 2023-01-16 | 法商賽諾菲公司 | Treatment of breast cancer with amcenestrant and palbociclib |
TW202304425A (en) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | Combination comprising ribociclib and amcenestrant |
KR20230130261A (en) | 2022-03-03 | 2023-09-12 | 인하대학교 산학협력단 | Composition for preventing or treating cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11260057B2 (en) * | 2017-07-24 | 2022-03-01 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06506467A (en) | 1991-03-08 | 1994-07-21 | ローヌ−プーラン ローラー インターナショナル(ホウルディングス) インコーポレイテッド | Polycyclic tertiary amine polyaromatic squalene synthetase inhibitor |
DE19833786A1 (en) | 1998-07-18 | 2000-01-20 | Schering Ag | New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy |
ATE286893T1 (en) | 2001-01-24 | 2005-01-15 | Chiesi Farma Spa | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS |
EE200400061A (en) | 2001-08-11 | 2004-04-15 | Bristol-Myers Squibb Pharma Company | Triphenylethylene Derivatives as Selective Estrogen Receptor Modulators and Pharmaceutical Compositions Containing Them |
SI1501819T1 (en) | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Estrogen receptor modulators |
CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
AU2005267385B2 (en) | 2004-06-25 | 2011-11-10 | Janssen Pharmaceutica N.V. | Quaternary salt CCR2 antagonists |
EP1896391B1 (en) | 2005-06-14 | 2015-08-12 | Baylor University | Combretastatin analogs with tubulin binding activity |
US8127618B1 (en) | 2007-05-18 | 2012-03-06 | Pacesetter, Inc. | Implantable micro-electromechanical system sensor |
EP2048126A1 (en) | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptane derivatives as selectively active oestrogens |
DE102010030538A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
ES2586908T3 (en) | 2010-12-24 | 2016-10-19 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
DE102011087987A1 (en) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
JP2015504049A (en) | 2011-12-30 | 2015-02-05 | センタウルス・バイオファーマ・カンパニー・リミテッドCentaurus Biopharma Co.,Ltd. | Novel aryl alkene derivatives and their use in selective estrogen receptor modulators |
CN102584687A (en) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | Ethylene derivatives used as selective estrogen receptor modulators |
LT3033086T (en) * | 2013-08-14 | 2021-12-27 | Novartis Ag | Combination therapy for the treatment of cancer |
WO2015028409A1 (en) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulene derivatives, method for the preparation thereof, pharmaceutical preparations comprising them, and the use thereof for producing medicaments |
RS60824B1 (en) | 2014-12-18 | 2020-10-30 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
AR104068A1 (en) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT |
CN113288887A (en) * | 2015-04-29 | 2021-08-24 | 雷迪厄斯制药公司 | Methods for treating cancer |
CN106924210A (en) * | 2015-12-29 | 2017-07-07 | 北京新领先医药科技发展有限公司 | A kind of capsule containing Pabuk former times profit cloth and preparation method thereof |
HUE057892T2 (en) | 2016-02-15 | 2022-06-28 | Sanofi Sa | Processes and intermediates for the preparation of novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds |
AU2017362460B2 (en) | 2016-11-17 | 2021-07-22 | Sanofi | Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
HUE059362T2 (en) | 2018-09-07 | 2022-11-28 | Sanofi Sa | Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof |
CA3119742A1 (en) * | 2018-11-16 | 2020-05-22 | Arqule, Inc. | Pharmaceutical combination for treatment of cancer |
-
2017
- 2017-07-25 EP EP17305998.1A patent/EP3434272A1/en not_active Ceased
-
2018
- 2018-07-23 MA MA49673A patent/MA49673B1/en unknown
- 2018-07-23 MY MYPI2020000179A patent/MY195271A/en unknown
- 2018-07-23 DK DK18740615.2T patent/DK3658147T3/en active
- 2018-07-23 WO PCT/EP2018/069901 patent/WO2019020559A1/en unknown
- 2018-07-23 HU HUE18740615A patent/HUE057271T2/en unknown
- 2018-07-23 HR HRP20212030TT patent/HRP20212030T1/en unknown
- 2018-07-23 RS RS20220068A patent/RS62837B1/en unknown
- 2018-07-23 PT PT187406152T patent/PT3658147T/en unknown
- 2018-07-23 ES ES18740615T patent/ES2906279T3/en active Active
- 2018-07-23 KR KR1020207002003A patent/KR20200031622A/en not_active Application Discontinuation
- 2018-07-23 LT LTEPPCT/EP2018/069901T patent/LT3658147T/en unknown
- 2018-07-23 JP JP2020503737A patent/JP6741897B1/en active Active
- 2018-07-23 AU AU2018308871A patent/AU2018308871A1/en active Pending
- 2018-07-23 CA CA3070754A patent/CA3070754A1/en active Pending
- 2018-07-23 EP EP18740615.2A patent/EP3658147B1/en active Active
- 2018-07-23 RU RU2020107416A patent/RU2764116C2/en active
- 2018-07-23 BR BR112020001398-6A patent/BR112020001398A2/en active Search and Examination
- 2018-07-23 CN CN201880048755.5A patent/CN111107851B/en active Active
- 2018-07-23 US US16/634,089 patent/US11260057B2/en active Active
- 2018-07-23 IL IL272166A patent/IL272166B2/en unknown
- 2018-07-23 SG SG11202000367RA patent/SG11202000367RA/en unknown
- 2018-07-23 PL PL18740615T patent/PL3658147T3/en unknown
- 2018-07-23 SI SI201830528T patent/SI3658147T1/en unknown
- 2018-07-24 AR ARP180102058 patent/AR112284A1/en unknown
- 2018-07-24 UY UY0001037818A patent/UY37818A/en not_active Application Discontinuation
- 2018-07-24 TW TW107125442A patent/TWI768087B/en active
-
2020
- 2020-01-09 ZA ZA2020/00145A patent/ZA202000145B/en unknown
- 2020-01-10 PH PH12020500091A patent/PH12020500091A1/en unknown
- 2020-01-13 CO CONC2020/0000240A patent/CO2020000240A2/en unknown
-
2022
- 2022-01-19 US US17/579,187 patent/US20220362248A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11260057B2 (en) * | 2017-07-24 | 2022-03-01 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11713296B2 (en) | 2018-09-07 | 2023-08-01 | Sanofi | Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-l-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate and preparation process thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220362248A1 (en) | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer | |
EP2694485B1 (en) | Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments | |
EP2694073B1 (en) | Combinations of akt and mek inhibitors for treating cancer | |
CA3163095A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
JP2021534115A (en) | Treatment of B-cell malignancies | |
CN111821302A (en) | Quinolines for the combined treatment of chondrosarcoma | |
US20230404971A1 (en) | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | |
EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
JP2015515476A (en) | Method for treating cancer using PI3K inhibitor and MEK inhibitor | |
EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
CN111821459A (en) | Quinolines for the combined treatment of osteosarcoma | |
NZ617243B2 (en) | Combinations of akt and mek inhibitor compounds, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |